Antibody persistence and the effect of a booster dose given 5, 10 or 15years after vaccinating preadolescents with a recombinant hepatitis B vaccine

Vaccine

Volumn 31, Issue 3, 2013, Pages 448-451

  Gilca, Vladimir ^a   De Serres, Gaston ^a   Boulianne, Nicole ^a   Murphy, Donald ^b   De Wals, Philippe ^a   Ouakki, Manale ^a   Trudeau, Gisele ^c   Massé, Richard ^d   Dionne, Marc ^a  

^a UNIVERSITÉ LAVAL   (Canada)

^b INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^c Direction Régionale de Santé Publique de la Capital Nationale   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Antibody and immune memory persistence; Hepatitis B; Vaccination

Indexed keywords

HEPATITIS B ANTIBODY; RECOMBINANT HEPATITIS B VACCINE;

ABSENCE OF SIDE EFFECTS; ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; DRUG TOLERABILITY; HEPATITIS B; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION; VIRUS IMMUNITY;

ADULT; CHILD; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; IMMUNOLOGIC MEMORY; TIME FACTORS; VACCINES, SYNTHETIC;

EID: 84871652052     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.11.037     Document Type: Article

References (20)

1. Plotkin S.A., Orenstein W.A., Offit P.A. Vaccines 2008, Saunders Elsevier, Philadelphia. 5th ed.
2. Mast E.E., Weinbaum C.M., Fiore A.E., Alter M.J., Bell B.P., Finelli L., et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006, 55(December (8)). (RR-16):1-33; quiz CE1-4.
3. Zanetti A.R., Mariano A., Romano L., D'Amelio R., Chironna M., Coppola R.C., et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005, 366(October (9494)):1379-1384.
4. Greenberg D.P., Vadheim C.M., Marcy S.M., Partridge S., Jing J., Chiu C.Y., et al. Safety and immunogenicity of a recombinant hepatitis B vaccine administered to infants at 2, 4, and 6months of age. Vaccine 1996, 14(8):811-816.
5. Curran M.P., Goa K.L. DTPa-HBV-IPV/Hib vaccine (Infanrix hexa). Drugs 2003, 63(7):673-682. discussion 83-4.
6. Duval B., Boulianne N., De Serres G., Laflamme N., De Wals P., Massé R., et al. Comparative immunogenicity under field conditions of two recombinant hepatitis B vaccines in 8-10-year-old children. Vaccine 2000, 18:1467-1472.
7. Chaves S.S., Fischer G., Groeger J., Patel P.R., Thompson N.D., Teshale E.H., et al. Persistence of long-term immunity to hepatitis B among adolescents immunized at birth. Vaccine 2012, 30(February (9)):1644-1649.
8. Bialek S.R., Bower W.A., Novak R., Helgenberger L., Auerbach S.B., Williams I.T., et al. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study. The Pediatric Infectious Disease Journal 2008, 27(October (10)):881-885.
9. Hammitt L.L., Hennessy T.W., Fiore A.E., Zanis C., Hummel K.B., Dunaway E., et al. Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15years. Vaccine 2007, 25(September (39-40)):6958-6964.
10. Poovorawan Y., Chongsrisawat V., Theamboonlers A., Bock H.L., Leyssen M., Jacquet J.M. Persistence of antibodies and immune memory to hepatitis B vaccine 20years after infant vaccination in Thailand. Vaccine 2010, 28(January (3)):730-736.
11. Poorolajal J., Mahmoodi M., Majdzadeh R., Nasseri-Moghaddam S., Haghdoost A., Fotouhi A. Long-term protection provided by hepatitis B vaccine and need for booster dose: a meta-analysis. Vaccine 2010, 28(January (3)):623-631.
12. Wu Q., Zhuang G.H., Wang X.L., Wang L.R., Li N., Zhang M. Antibody levels and immune memory 23years after primary plasma-derived hepatitis B vaccination: results of a randomized placebo-controlled trial cohort from China where endemicity is high. Vaccine 2011, 29(March (12)):2302-2307.
13. Gilca V., De Serres G., Boulianne N., De Wals P., Murphy D., Trudeau G., et al. Antibody and immune memory persistence after vaccination of preadolescents with low doses of recombinant hepatitis B vaccine. Hum Vaccin 2010, 6(February (2)).
14. Petersen K.M., Bulkow L.R., McMahon B.J., Zanis C., Getty M., Peters H., et al. Duration of hepatitis B immunity in low risk children receiving hepatitis B vaccinations from birth. The Pediatric Infectious Disease Journal 2004, 23(July (7)):650-655.
15. Gabbuti A., Romano L., Blanc P., Meacci F., Amendola A., Mele A., et al. Long-term immunogenicity of hepatitis B vaccination in a cohort of Italian healthy adolescents. Vaccine 2007, 25(April (16)):3129-3132.
16. Samandari T., Fiore A.E., Negus S., Williams J.L., Kuhnert W., McMahon B.J., et al. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy. Pediatrics 2007, 120(August (2)):e373-e381.
17. Duval B., Gilca V., Boulianne N., De Wals P., Masse R., Trudeau G., et al. Comparative long term immunogenicity of two recombinant hepatitis B vaccines and the effect of a booster dose given after five years in a low endemicity country. The Pediatric Infectious Disease Journal 2005, 24(March (3)):213-218.
18. Gilca V., De Serres G., Boulianne N., De Wals P., Trudeau G., Masse R., et al. Antibody kinetics among 8-10years old respondents to hepatitis B vaccination in a low endemic country and the effect of a booster dose given five or ten years later. Vaccine 2009, 27(October (43)):6048-6053.
19. European Consensus Group Are booster immunisations needed for lifelong hepatitis B immunity?. Lancet 2000, 355:561-565.
20. Fortin C, Frigon M, Laliberté D, Thériault N, Tremblay G, Trudeau G, et al. Maladies à déclaration obligatoire - Intoxications, infections et autres événements sous surveillance. Rapport annuel 2010. Québec: Agence de la santé et des services sociaux de la Capitale-Nationale; 2011 Juin 2011. Report No.: ISBN: 978-2-89616-125-6.